dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Yap, Timothy A. |
dc.contributor.author | Vieito Villar, Maria |
dc.contributor.author | Baldini, Capucine |
dc.contributor.author | Sepúlveda, Juan Manuel |
dc.contributor.author | Kondo, Shunsuke |
dc.contributor.author | Simonelli, Matteo |
dc.date.accessioned | 2022-01-27T09:59:39Z |
dc.date.available | 2022-01-27T09:59:39Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, et al. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec;27(24):6666–76. |
dc.identifier.issn | 1557-3265 |
dc.identifier.uri | https://hdl.handle.net/11351/6913 |
dc.description | Càncer avançat; Factor de creixement transformador beta |
dc.language.iso | eng |
dc.publisher | American Association for Cancer Research |
dc.relation.ispartofseries | Clinical Cancer Research;27(24) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Quimioteràpia combinada |
dc.subject | Càncer - Quimioteràpia - Complicacions |
dc.subject | Medicaments - Efectes secundaris |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Combined Modality Therapy |
dc.subject.mesh | /adverse effects |
dc.title | First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-1504 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | tratamiento combinado |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1158/1078-0432.CCR-21-1504 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Yap TA] Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. [Vieito M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Baldini C] Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France. [Sepúlveda-Sánchez JM] Hospital Universitario 12 de Octubre, Madrid, Spain. [Kondo S] National Cancer Center Hospital, Tokyo, Japan. [Simonelli M] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Cancer Center, Humanitas Research Hospital, Milan, Italy |
dc.identifier.pmid | 34548321 |
dc.identifier.wos | 000732481500001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |